Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


Strength in Ziopharm continues to puzzle me. Perhaps a halo effect from Intrexon's S-1 filing? I remain hopeful that Pali ends up creating value. Looking for readout in brain cancer later this Fall.

Disclosure: I am long ZIOP.